Your browser doesn't support javascript.
loading
Frequency, Penetrance, and Variable Expressivity of Dilated Cardiomyopathy-Associated Putative Pathogenic Gene Variants in UK Biobank Participants.
Shah, Ravi A; Asatryan, Babken; Sharaf Dabbagh, Ghaith; Aung, Nay; Khanji, Mohammed Y; Lopes, Luis R; van Duijvenboden, Stefan; Holmes, Anthony; Muser, Daniele; Landstrom, Andrew P; Lee, Aaron Mark; Arora, Pankaj; Semsarian, Christopher; Somers, Virend K; Owens, Anjali T; Munroe, Patricia B; Petersen, Steffen E; Chahal, C Anwar A.
Affiliation
  • Shah RA; Imperial College Healthcare NHS Trust, London, United Kingdom (R.A.S.).
  • Asatryan B; Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Switzerland (B.A.).
  • Sharaf Dabbagh G; Center for Inherited Cardiovascular Diseases, WellSpan Health, Lancaster, PA (G.S.D., C.A.A.C.).
  • Aung N; University of Michigan, Division of Cardiovascular Medicine, Ann Arbor (G.S.D.).
  • Khanji MY; Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom (N.A., M.Y.K., L.R.L., A.M.L., S.E.P., C.A.A.C.).
  • Lopes LR; NIHR Barts Biomedical Research Centre, William Harvey Research Institute, Queen Mary University of London, United Kingdom (N.A., M.Y.K., S.v.D., A.M.L., P.B.M., S.E.P.).
  • van Duijvenboden S; Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom (N.A., M.Y.K., L.R.L., A.M.L., S.E.P., C.A.A.C.).
  • Holmes A; NIHR Barts Biomedical Research Centre, William Harvey Research Institute, Queen Mary University of London, United Kingdom (N.A., M.Y.K., S.v.D., A.M.L., P.B.M., S.E.P.).
  • Muser D; Centre for Heart Muscle Disease, Institute of Cardiovascular Science, University College London, United Kingdom (L.R.L.).
  • Landstrom AP; NIHR Barts Biomedical Research Centre, William Harvey Research Institute, Queen Mary University of London, United Kingdom (N.A., M.Y.K., S.v.D., A.M.L., P.B.M., S.E.P.).
  • Lee AM; GE Healthcare, Chicago, IL (A.H.).
  • Arora P; Cardiac Electrophysiology, Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia (D.M., C.A.A.C.).
  • Semsarian C; Departments of Pediatrics, Division of Cardiology, and Cell Biology, Duke University School of Medicine, Durham, NC (A.P.L.).
  • Somers VK; NIHR Barts Biomedical Research Centre, William Harvey Research Institute, Queen Mary University of London, United Kingdom (N.A., M.Y.K., S.v.D., A.M.L., P.B.M., S.E.P.).
  • Owens AT; Division of Cardiovascular Disease, University of Alabama at Birmingham (P.A.).
  • Munroe PB; Agnes Ginges Centre for Molecular Cardiology at Centenary Institute (C.S.), The University of Sydney, New South Wales, Australia.
  • Petersen SE; Sydney Medical School Faculty of Medicine and Health (C.S.), The University of Sydney, New South Wales, Australia.
  • Chahal CAA; Department of Cardiology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia (C.S.).
Circulation ; 146(2): 110-124, 2022 07 12.
Article in En | MEDLINE | ID: mdl-35708014
ABSTRACT

BACKGROUND:

There is a paucity of data regarding the phenotype of dilated cardiomyopathy (DCM) gene variants in the general population. We aimed to determine the frequency and penetrance of DCM-associated putative pathogenic gene variants in a general adult population, with a focus on the expression of clinical and subclinical phenotype, including structural, functional, and arrhythmic disease features.

METHODS:

UK Biobank participants who had undergone whole exome sequencing, ECG, and cardiovascular magnetic resonance imaging were selected for study. Three variant-calling strategies (1 primary and 2 secondary) were used to identify participants with putative pathogenic variants in 44 DCM genes. The observed phenotype was graded DCM (clinical or cardiovascular magnetic resonance diagnosis); early DCM features, including arrhythmia or conduction disease, isolated ventricular dilation, and hypokinetic nondilated cardiomyopathy; or phenotype-negative.

RESULTS:

Among 18 665 individuals included in the study, 1463 (7.8%) possessed ≥1 putative pathogenic variant in 44 DCM genes by the main variant calling strategy. A clinical diagnosis of DCM was present in 0.34% and early DCM features in 5.7% of individuals with putative pathogenic variants. ECG and cardiovascular magnetic resonance analysis revealed evidence of subclinical DCM in an additional 1.6% and early DCM features in an additional 15.9% of individuals with putative pathogenic variants. Arrhythmias or conduction disease (15.2%) were the most common early DCM features, followed by hypokinetic nondilated cardiomyopathy (4%). The combined clinical/subclinical penetrance was ≤30% with all 3 variant filtering strategies. Clinical DCM was slightly more prevalent among participants with putative pathogenic variants in definitive/strong evidence genes as compared with those with variants in moderate/limited evidence genes.

CONCLUSIONS:

In the UK Biobank, ≈1 of 6 of adults with putative pathogenic variants in DCM genes exhibited early DCM features potentially associated with DCM genotype, most commonly manifesting with arrhythmias in the absence of substantial ventricular dilation or dysfunction.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiomyopathy, Dilated / Cardiomyopathies Type of study: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Country/Region as subject: Europa Language: En Journal: Circulation Year: 2022 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiomyopathy, Dilated / Cardiomyopathies Type of study: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Country/Region as subject: Europa Language: En Journal: Circulation Year: 2022 Document type: Article